Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

An analysis of data from the phase II IMbark study, presented at the 2020 ASH Annual Meeting, showed that higher doses of the telomerase inhibitor imetelstat (9.4 mg/kg vs. 4.7 mg/kg) improved median overall survival (28.1 vs. 19.9 months, respectively) among patients with relapsed/refractory myelofibrosis who previously received JAK inhibitor therapy.